AbbVie (NYSE:ABBV) Stock Keeps Outperform Rating at Royal Bank Of Canada

AbbVie (NYSE:ABBV)‘s stock had its “outperform” rating reiterated by Royal Bank Of Canada in a report issued on Tuesday, Benzinga reports. They currently have a $280.00 price objective on the stock. Royal Bank Of Canada’s price objective points to a potential upside of 1.88% from the stock’s current price.

A number of other analysts have also commented on ABBV. BNP Paribas Exane boosted their price target on AbbVie from $218.00 to $247.00 and gave the company a “neutral” rating in a report on Tuesday, August 11th. Sanford C. Bernstein reiterated a “market perform” rating and set a $225.00 price objective (up from $203.00) on shares of AbbVie in a report on Tuesday, June 23rd. Rothschild & Co Redburn increased their price objective on AbbVie from $284.00 to $285.00 and gave the stock a “buy” rating in a report on Tuesday, August 4th. UBS Group boosted their target price on AbbVie from $260.00 to $275.00 and gave the company a “neutral” rating in a research note on Tuesday, October 6th. Finally, Leerink Partners upped their price target on AbbVie from $245.00 to $279.00 and gave the stock an “outperform” rating in a research report on Wednesday, August 5th. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat.com, AbbVie presently has a consensus rating of “Moderate Buy” and a consensus target price of $277.18.

AbbVie Trading Down 2.2%

Shares of ABBV stock traded down $6.30 during trading hours on Tuesday, hitting $274.82. 6,391,188 shares of the company were exchanged, compared to its average volume of 6,398,982. The business has a 50 day moving average of $259.79 and a two-hundred day moving average of $237.39. AbbVie has a 52 week low of $190.75 and a 52 week high of $283.43. The company has a market capitalization of $485.55 billion, a PE ratio of 77.63, a PEG ratio of 1.26 and a beta of 0.24.

AbbVie (NYSE:ABBV) last posted its quarterly earnings data on Friday, July 31st. The company reported $3.65 EPS for the quarter, beating the consensus estimate of $3.61 by $0.04. The business had revenue of $16.99 billion for the quarter, compared to analysts’ expectations of $16.80 billion. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The firm’s revenue was up 10.2% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.97 EPS. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. On average, research analysts forecast that AbbVie will post 13.94 EPS for the current year.

Insiders Place Their Bets

In related news, EVP Nicholas Donoghoe sold 32,710 shares of the business’s stock in a transaction on Friday, August 14th. The shares were sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the transaction, the executive vice president directly owned 74,430 shares in the company, valued at approximately $18,607,500. The trade was a 30.53% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 0.06% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the company. Burk Holdings LLC purchased a new position in shares of AbbVie in the second quarter worth about $30,000. Marquette Asset Management LLC grew its position in AbbVie by 52.2% during the 2nd quarter. Marquette Asset Management LLC now owns 140 shares of the company’s stock worth $35,000 after acquiring an additional 48 shares during the last quarter. Abound Financial LLC bought a new position in AbbVie during the 4th quarter worth approximately $32,000. Principia Wealth Advisory LLC increased its stake in AbbVie by 38.9% in the 2nd quarter. Principia Wealth Advisory LLC now owns 157 shares of the company’s stock worth $40,000 after purchasing an additional 44 shares during the period. Finally, Merkkuri Wealth Advisors LLC purchased a new position in AbbVie in the 1st quarter worth approximately $34,000. 70.23% of the stock is currently owned by institutional investors and hedge funds.

AbbVie News Roundup

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Fresh clinical and regulatory developments are strengthening AbbVie’s long-term growth story. Phase 3 data for SKYRIZI and RINVOQ in Crohn’s disease, Breakthrough Therapy Designations for temab-A in colorectal and lung cancer, and early obesity-treatment data could expand the company’s pipeline beyond its existing immunology franchise. AbbVie Could Be 44% Below Fair Value On Fresh Pipeline Wins
• Positive Sentiment: Long-term SKYRIZI and RINVOQ data presented at ACG 2026 support the view that the two drugs can continue offsetting the loss of Humira revenue. Their expected contribution is a key focus ahead of AbbVie’s next earnings report. AbbVie Highlights Long-Term SKYRIZI, RINVOQ Data Findings
• Positive Sentiment: Royal Bank of Canada reaffirmed its “outperform” rating and assigned a $280 price target, signaling continued confidence in AbbVie’s earnings and pipeline execution. RBC Reaffirms AbbVie Outperform Rating
• Neutral Sentiment: Analysts continue comparing AbbVie with Eli Lilly, highlighting AbbVie’s diversified immunology growth while noting Lilly’s stronger exposure to the rapidly expanding cardiometabolic market. AbbVie vs. Eli Lilly
• Negative Sentiment: Despite encouraging developments, AbbVie trades at a high earnings multiple after a substantial rally, while RBC’s $280 target implies only limited upside. Ongoing Humira erosion, rising immunology competition, and uncertainty around pipeline commercialization may be prompting profit-taking and valuation concerns.

AbbVie Company Profile

AbbVie Inc is a global biopharmaceutical company that develops, manufactures and markets medicines for a range of serious and chronic health conditions. Its portfolio spans immunology, oncology, neuroscience, eye care, aesthetics, gastroenterology and women’s health.

The company’s products include the immunology medicines Skyrizi and Rinvoq; neuroscience treatments such as Vraylar, Ubrelvy and Qulipta; and oncology medicines including Imbruvica and Venclexta. AbbVie also markets Botox Cosmetic and Botox Therapeutic, as well as other products for aesthetics, eye care and specialty care.

AbbVie was established in 2013 as an independent, publicly traded company following its separation from Abbott Laboratories.